Sanofi Active Ingredients Solutions Overview

Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. 

The company will invest €400 million per year to advance mRNA technology beyond the pandemic

List of active API's manufactured by Sanofi.

Commercialisation activities for the US market are already underway for Fluzone High-Dose Quadrivalent

French company is now providing manufacturing capacity to support three different COVID-19 vaccines

The company will invest €400 million in a new site to enable it to produce vaccines on a massive scale for Asia

The companies anticipate first results of Phase I/II in early December 2020, to support the initiation of a pivotal Phase III study before the end of the year.

The transaction will enable Sanofi to expand and accelerate development of BTK inhibitors across multiple indications, including MS and other central nervous system diseases.

Discussions relate to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.

Sanofi's plans to create a European company to manufacture and market active pharmaceutical ingredients (APIs) should help to balance the region's heavy reliance on sourcing them from Asian markets, the French pharmaceutical firm said Monday.

Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.